Faculty: Omid Hamid, MD, Genevieve Boland, MD, PhD, Mark Faries, MD and Charlotte Ariyan, MD
Learn about the mechanisms of action and toxicities of novel immunotherapeutic agents for metastatic melanoma and how to best integrate these agents with surgical options. Four specific topics will be covered including: systemic therapy, immune adjuvants for Stage IV melanoma, management of oligometastatic disease and surgical outcomes in melanoma in combination with immunotherapy.
You may find this activity in the Melanoma Disease section in the ExpertED@SSO catalog.
This activity is partially supported by independent educational grants from Amgen, Bristol Myers Squibb and Merck.